The article argues that framing semaglutide and tirzepatide as 'appetite suppressants' fundamentally mischaracterizes their mechanism. GLP-1 receptors are densely expressed in the vagus nerve, hypothalamus, and dopamine reward circuits (VTA and nucleus accumbens), meaning caloric reduction is a downstream consequence of broad neuromodulation rather than the primary action.
The editorial reinforces that the receptor distribution predicts the off-label effects users are reporting — reduced alcohol cravings, nicotine indifference, dampened compulsive shopping. These cross-domain effects only make sense if the drugs are acting as systemic reward-circuit modulators, not as gut-localized satiety signals.
The 347-comment thread surfaces consistent first-person reports: reduced alcohol cravings, ex-smokers losing interest in nicotine, and one engineer noting compulsive online shopping went quiet within three weeks on a low dose. Commenters frame these as evidence that the FDA label dramatically understates what the drugs do.
Argues the gut-brain axis is concrete neuroanatomy, not metaphor: vagal afferents outnumber efferents 9-to-1, the enteric nervous system contains ~500 million neurons, and the microbiome produces short-chain fatty acids, bile acid derivatives, and tryptophan metabolites that modulate CNS function. GLP-1 agonists intervene at multiple nodes in this established circuit.
A Psychology Today piece by the Mood by Microbe team — the same group that's been publishing on the gut-brain axis for the better part of a decade — pulled together the current evidence on what semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) actually do once they hit the bloodstream. The headline finding isn't new to neuroscientists, but it's news to most of the developer-investor-product crowd building around the GLP-1 boom: these drugs are not appetite suppressants in any meaningful mechanistic sense. They are systemic gut-brain axis modulators that happen to reduce caloric intake as a downstream effect.
The post hit 155 on Hacker News with a comment section that's unusually substantive — practitioners describing reduced alcohol cravings, ex-smokers reporting nicotine indifference, and at least one engineer noting their compulsive online shopping went quiet within three weeks of starting a low dose. None of those effects show up on the FDA label. All of them are predicted by the receptor distribution.
GLP-1 receptors are expressed in the pancreas (the diabetes mechanism everyone knows about), but they're also dense in the nodose ganglion of the vagus nerve, the arcuate nucleus of the hypothalamus, and — critically — the ventral tegmental area and nucleus accumbens, the dopamine circuits that govern reward and craving. Semaglutide crosses the blood-brain barrier in small but pharmacologically meaningful amounts. Tirzepatide, which adds GIP agonism, hits a partially overlapping but distinct receptor map.
The gut-brain axis isn't a metaphor. It's a bidirectional signaling system involving the vagus nerve (afferent fibers outnumber efferent roughly 9-to-1, meaning the gut talks to the brain far more than the other way around), the enteric nervous system (~500 million neurons embedded in the gut wall), and the microbiome's metabolic outputs — short-chain fatty acids, bile acid derivatives, and tryptophan metabolites that either cross the BBB or signal through vagal receptors.
When you give someone a GLP-1 agonist, you're not just slowing gastric emptying. You're modulating vagal afferent firing, shifting the microbiome composition (multiple studies now show reductions in Firmicutes and increases in Akkermansia muciniphila within 8-12 weeks), and directly dampening dopamine release in reward circuits in response to food, alcohol, and likely other addictive stimuli. The reason patients report a 'quieting' of food noise — the constant background mental chatter about what to eat next — is that you've turned down the gain on the brain's salience-attribution machinery, not just made their stomach feel full.
This matters for three reasons that go beyond the obesity-drug narrative. First, it explains the rapidly accumulating off-label evidence. A University of Pennsylvania retrospective on 230,000 patients found semaglutide users had a 40% lower incidence of new-onset alcohol use disorder. A Danish registry study found a 49% reduction in opioid overdose risk among diabetics on GLP-1s vs. those on other antidiabetics. These aren't appetite effects. They're reward-circuit effects.
Second, it predicts side effects that the marketing has soft-pedaled. Anhedonia — the flattening of pleasure response — is showing up in patient forums with concerning frequency. If you're dampening reward signaling, you're dampening *all* reward signaling, not just food reward. Some users describe a kind of emotional grayscale. The same mechanism that makes a cigarette uninteresting can make a hobby uninteresting.
Third, it reframes the microbiome angle. The microbiome shifts aren't a side effect of eating less — they appear to be partially mediated by direct receptor binding in the gut wall, which means the drug is restructuring the ecology of your digestive tract independent of food intake. Whether those shifts persist after discontinuation is an open question with weak data so far. Early signals suggest partial reversion within 6 months but with persistent changes to certain commensal populations.
The HN comment thread surfaced a useful framing from a clinician: think of GLP-1 agonists less like statins (single-target enzyme inhibition with a clean mechanism) and more like SSRIs (broad neuromodulation with effects that take months to fully manifest and that we still don't fully understand 35 years in). That's a useful prior for anyone trying to model the long-term population-scale effects.
If you're building in digital health, the product category lines are now load-bearing fiction. An app that does 'weight loss coaching' and a separate app that does 'sobriety support' are, mechanistically, intervening on overlapping neural circuits — and your users on GLP-1s are getting that intervention pharmacologically whether your product addresses it or not. Your engagement metrics on habit-tracking apps will look different for the ~12% of US adults now on a GLP-1, and you should probably be segmenting analytics accordingly.
If you're in mental health tech, the assumption that mood disorders are downstream of brain chemistry alone is increasingly hard to defend. Vagal nerve stimulation is already an approved depression treatment. Psilocybin trials show gut-microbiome correlations with response. The drug class that's about to be in 30 million American medicine cabinets directly modulates the same axis. Building mood-tracking features that don't capture GI symptoms, recent antibiotic use, or GLP-1 status is leaving signal on the floor.
If you're in consumer subscription businesses — alcohol, gambling, fast food, retail — the early evidence is that the addressable market for compulsive-purchase behavior is structurally shrinking. Diageo's CFO already flagged GLP-1s as a watch-item on the last earnings call. The mechanism predicts this isn't a temporary fad effect.
The interesting frontier isn't whether GLP-1 agonists work — they obviously do — but what the second-generation drugs look like when designers can target receptor subtypes more precisely. Eli Lilly's retatrutide (triple agonist: GLP-1 + GIP + glucagon) is in Phase 3 and produces 24% weight loss at 48 weeks. Amgen's MariTide hits GLP-1 plus blocks GIP. Each receptor combination will produce a different psychological side-effect profile, and the field has approximately zero validated tools for predicting which one. We're about to run the largest uncontrolled neuropharmacology experiment in human history, and the read-outs will mostly come from Reddit threads and insurance claims data before they show up in journals. If you're building data infrastructure that could surface those signals — phenotype extraction from EHRs, longitudinal patient-reported outcomes, microbiome time series — the next five years are going to need it.
Studies show almost all subjects regained the weight and reversed gains within 2 years. This means underlying issues (e.g., food addiction) aren't being addressed. Short of changing habits, the only maintenance solution is lifelong drug use and that doesn't sit well with me.
Metabolic theories of mental illnesses and cancer are seriously understudied.
Tirzepatide at 1mg/week reduced my muscle soreness. I felt less depressed but this might just have been situational because I've been plagued by bad soreness after working out for years.Unfortunately after twelve weeks I had to stop because I felt a lot of nausea and tenderness in my upper
As a habitual habit developer, Im keeping my hopes up that in 5 or 10 years, this is something that can help me and many others.I've read experiences from people on illicit substances that claimed they helped them quit.It would be beat if this carried over to things like caffeine/nicotine&
Top 10 dev stories every morning at 8am UTC. AI-curated. Retro terminal HTML email.
I'd take them even if they didn't make me lose weight - and I'm the type of person that doesn't like takeing Tylenol unless absolutely necessary.The best way I can describe it: my body and mind are no longer is in starvation mode. I plan, do, act and sleep well.